<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00543426</url>
  </required_header>
  <id_info>
    <org_study_id>06DZ19728</org_study_id>
    <nct_id>NCT00543426</nct_id>
  </id_info>
  <brief_title>Fuzheng Huayu Tablets Against Posthepatitic Cirrhosis</brief_title>
  <official_title>Fuzheng Huayu Tablets Against Posthepatitic Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai University of Traditional Chinese Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of the trial is adopted Fuzheng Huayu tablets against posthepatitic
      cirrhosis, and to build a standard evaluation system for efficacy of traditional Chinese
      medicine (TCM).

      The second purpose is according to the international clinical guideline and the specialty of
      TCM to build a standard clinical trial regulation for traditional Chinese medicine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the value of Child-Pugh and symptoms scale for Posthepatitic Cirrhosis</measure>
    <time_frame>six months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>hepatic function; blood test; blood ammonia and blood sugar determination</measure>
    <time_frame>six months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Posthepatitic Cirrhosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fuzheng Huayu Tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>sham Fuzheng Huayu Tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fuzheng Huayu Tablets</intervention_name>
    <description>Tablet,three times a day,four tablets one time</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sham Fuzheng Huayu Tablets (placebo)</intervention_name>
    <description>Tablet, three times a day, four tablets one time</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of B Post hepatitic cirrhosis.

          -  Male or female patients between 18~65 years old.

          -  Written informed consent.

        Exclusion Criteria:

          -  Child-Pugh C above 12, or ALT &gt; 2×ULN, TBiL &gt; 2×ULN, or combined with hepatic
             encephacopathy, Obstinate ascites, bleeding tendency, hepato-renal syndrome, or
             primary liver cancer.

          -  Combined with severe heart, gallbladder, kidney, endocrine system, hemopoietic system
             or nervous system disease.

          -  Deformed man by the law.

          -  Pregnancy or breast feeding women, or unwilling to have contraception.

          -  Irritability body constitution, or irritability of the Fuzheng Huayu Capsules.

          -  Enter other trials lately one month.

          -  Other cause of cirrhosis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zengzeng Cai, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Shanghai Univercity of TCM</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shuguang Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>20021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Zhao CQ, Wu YQ, Xu LM. [Curative effects of Fuzheng Huayu capsules on hepatic fibrosis and the functional mechanisms: a review]. Zhong Xi Yi Jie He Xue Bao. 2006 Sep;4(5):467-72. Review. Chinese.</citation>
    <PMID>16965738</PMID>
  </reference>
  <reference>
    <citation>Liu P, Hu YY, Liu C, Xu LM, Liu CH, Sun KW, Hu DC, Yin YK, Zhou XQ, Wan MB, Cai X, Zhang ZQ, Ye J, Tang BZ, He J. [Multicenter clinical study about the action of Fuzheng Huayu Capsule against liver fibrosis with chronic hepatitis B]. Zhong Xi Yi Jie He Xue Bao. 2003 Jul;1(2):89-98, 102. Chinese.</citation>
    <PMID>15339577</PMID>
  </reference>
  <reference>
    <citation>Zhang Q, Zhang WT, Wei JJ, Wang XB, Liu P. [Combined use of factor analysis and cluster analysis in classification of traditional Chinese medical syndromes in patients with posthepatitic cirrhosis]. Zhong Xi Yi Jie He Xue Bao. 2005 Jan;3(1):14-8. Chinese.</citation>
    <PMID>15644152</PMID>
  </reference>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 12, 2007</study_first_submitted>
  <study_first_submitted_qc>October 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2007</study_first_posted>
  <last_update_submitted>March 6, 2013</last_update_submitted>
  <last_update_submitted_qc>March 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fuzheng Huayu Tablets</keyword>
  <keyword>Multicenter clinical study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

